{
    "clinical_study": {
        "@rank": "100770", 
        "acronym": "RDT-PEF", 
        "arm_group": [
            {
                "arm_group_label": "Renal sympathetic denervation", 
                "arm_group_type": "Experimental", 
                "description": "Renal denervation using the Medtronic Symplicity catheter."
            }, 
            {
                "arm_group_label": "Control", 
                "arm_group_type": "No Intervention", 
                "description": "HF-PEF patients who will serve as control."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether renal sympathetic denervation (RSD)(a\n      treatment that lowers the activity of the sympathetic nervous system) is useful in the\n      management of patients with heart failure with preserved ejection fraction (HF-PEF)."
        }, 
        "brief_title": "Renal Denervation in Heart Failure With Preserved Ejection Fraction", 
        "completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Cardiac Failure", 
        "condition_browse": {
            "mesh_term": "Heart Failure"
        }, 
        "detailed_description": {
            "textblock": "Increasing evidence suggests an important role of activation of the sympathetic nervous\n      system (SNS) in heart failure with preserved left ventricular ejection fraction. The current\n      study aims to evaluate efficacy  of renal sympathetic denervation for the modulation of the\n      SNS in patients with HF-PEF."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of HF-PEF using ESC 2012 guidelines\n\n          -  EF>50%\n\n          -  NHYA 2-3\n\n        Exclusion Criteria:\n\n          -  Previously documented EF<40%\n\n          -  Hypertrophic, restrictive, dilated cardiomyopathy\n\n          -  Significant valvular heart disease\n\n          -  Unfavourable renal artery anatomy for renal denervation\n\n          -  eGFR<45\n\n          -  Contraindication to MRI\n\n          -  Myocardial infarction, unstable angina or cerebrovascular accident in last 6 months"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01840059", 
            "org_study_id": "2012HS001B"
        }, 
        "intervention": {
            "arm_group_label": "Renal sympathetic denervation", 
            "description": "A fit for purpose radiofrequency catheter is guided to the renal artery using fluoroscopy. This is connected to an external RF generator. RF energy is applied through the catheter to the renal artery wall with the goal of disrupting the sympathetic nerves which run in the adventitia", 
            "intervention_name": "Renal sympathetic denervation", 
            "intervention_type": "Device", 
            "other_name": "Medtronic Symplicity Catheter"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Cardiac Failure", 
            "Autonomic Denervation"
        ], 
        "lastchanged_date": "April 22, 2013", 
        "location": {
            "contact": {
                "email": "h.patel3@rbht.nhs.uk", 
                "last_name": "Hitesh Patel"
            }, 
            "facility": {
                "address": {
                    "city": "London", 
                    "country": "United Kingdom", 
                    "zip": "SW3 6NP"
                }, 
                "name": "Royal Brompton Hospital"
            }, 
            "investigator": {
                "last_name": "Carlo di Mario", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomised Controlled Trial Investigating the Effect of Transcatheter Renal Sympathetic Denervation on Symptoms and Cardiac Function in Patients With Heart Failure With Preserved Ejection Fraction.", 
        "overall_contact": {
            "email": "h.patel3@rbht.nhs.uk", 
            "last_name": "Hitesh Patel"
        }, 
        "overall_official": {
            "affiliation": "Royal Brompton Hospital", 
            "last_name": "Carlo di Mario", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: National Health Service", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Minnesota Living with Heart Failure Questionnaire", 
                "measure": "Change in Symptoms", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Peak VO2 (Oxygen Uptake) on cardiopulmonary exercise testing", 
                "measure": "Change in Exercise Function", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "BNP (Natriuretic peptide)", 
                "measure": "Change in Heart Failure Biomarker", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "E/E' on echocardiography", 
                "measure": "Change in LV (Left Ventricle) filling pressure", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "LV mass index", 
                "measure": "Change in LV remodelling", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "LA volume index", 
                "measure": "Change in Left atrial (LA) size", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "reference": {
            "PMID": "22392370", 
            "citation": "Sobotka PA, Krum H, B\u00f6hm M, Francis DP, Schlaich MP. The role of renal denervation in the treatment of heart failure. Curr Cardiol Rep. 2012 Jun;14(3):285-92."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01840059"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Heart rate variability", 
                "measure": "Change in Autonomic function", 
                "safety_issue": "No", 
                "time_frame": "3 and 12 months"
            }, 
            {
                "description": "Urea and Creatinine", 
                "measure": "Change in Renal function", 
                "safety_issue": "Yes", 
                "time_frame": "3 and 12 months"
            }, 
            {
                "description": "Aorta MRI (Magnetic Resonance Imaging)", 
                "measure": "Change in Vascular function", 
                "safety_issue": "No", 
                "time_frame": "3 and 12 months"
            }, 
            {
                "description": "mIBG radiotracer assessment", 
                "measure": "Change in Autonomic function", 
                "safety_issue": "No", 
                "time_frame": "3 and 12 months"
            }, 
            {
                "description": "Neurohormones", 
                "measure": "Change in neurohormones", 
                "safety_issue": "No", 
                "time_frame": "3 and 12 months"
            }, 
            {
                "description": "Renal MRI", 
                "measure": "Change in renal blood flow", 
                "safety_issue": "Yes", 
                "time_frame": "3 and 12 months"
            }, 
            {
                "description": "ABPM (Ambulatory Blood Pressure Monitoring)", 
                "measure": "Change in Blood pressure", 
                "safety_issue": "No", 
                "time_frame": "3 and 12 months"
            }, 
            {
                "description": "EndoPat", 
                "measure": "Change in Endothelial function", 
                "safety_issue": "No", 
                "time_frame": "3 and 12 months"
            }
        ], 
        "source": "Royal Brompton & Harefield NHS Foundation Trust", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Royal Brompton & Harefield NHS Foundation Trust", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}